An Audit Strategy for Progression-Free Survival
Authors:
- 6 January 2011
- journal article
- Published by Oxford University Press (OUP) in Biometrics
- Vol. 67 (3) , 1092-1099
Abstract
Summary In randomized clinical trials, the use of potentially subjective endpoints has led to frequent use of blinded independent central review (BICR) and event adjudication committees to reduce possible bias in treatment effect estimators based on local evaluations (LE). In oncology trials, progression‐free survival (PFS) is one such endpoint. PFS requires image interpretation to determine whether a patient's cancer has progressed, and BICR has been advocated to reduce the potential for endpoints to be biased by knowledge of treatment assignment. There is current debate, however, about the value of such reviews with time‐to‐event outcomes such as PFS. We propose a BICR audit strategy as an alternative to a complete‐case BICR to provide assurance of the presence of a treatment effect. We develop an auxiliary‐variable estimator of the log‐hazard ratio that is more efficient than simply using the audited (i.e., sampled) BICR data for estimation. Our estimator incorporates information from the LE on all the cases and the audited BICR cases, and is an asymptotically unbiased estimator of the log‐hazard ratio from BICR. The estimator offers considerable efficiency gains that improve as the correlation between LE and BICR increases. A two‐stage auditing strategy is also proposed and evaluated through simulation studies. The method is applied retrospectively to a large oncology trial that had a complete‐case BICR, showing the potential for efficiency improvements.Keywords
This publication has 13 references indexed in Scilit:
- Measurement error in the timing of events: effect on survival analyses in randomized clinical trialsClinical Trials, 2010
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?Journal of Clinical Oncology, 2008
- Improving the efficiency of the log-rank test using auxiliary covariatesBiometrika, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Survival analysis using auxiliary variables via non‐parametric multiple imputationStatistics in Medicine, 2005
- Analysis of Health Surveys1999
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988
- Statistical Sampling in Auditing with Auxiliary Information EstimatorsJournal of Accounting Research, 1973